Ipilimumab for previously treated unresectable stage III or IV malignant melanoma
| Status: |
In progress |
| Expected date of issue: |
TBC |
| Referral date: |
November 2008 |
| Wave: |
CRS2 |
| Process: |
STA |
| Notes:
Cancer reform strategy batch 2
|
| Topic area:
|
NICE project team
| Executive Lead: |
TBC
|
| Technical Lead: |
Christian Griffiths
|
| Communications manager: |
Alice Law
|
| Project manager: |
Bijal Joshi
|
Provisional schedule
| Closing date for invited submissions / evidence submission: |
17 June 2011 |
| 1st appraisal committee meeting: |
20 September 2011 |
| 2nd appraisal committee meeting |
16 November 2011 |
| 3rd appraisal committee meeting: |
15 February 2012 |
Consultees and commentators
|
| Consultees |
Commentators (no right to submit or appeal)
|
|
Manufacturers/sponsors
- Bristol-Myers Squibb (ipilimumab)
Patient/carer groups
- Action for Sick Children
- Afiya Trust
- Association for Children with Life Threatening or Terminal Conditions
- Black Health Agency
- Cancer 52
- Cancer Black Care
- Cancer Equality
- CANCERactive
- Chinese National Healthy Living Centre
- CLIC Sargent
- Counsel and Care
- Equalities National Council
- Helen Rollason Heal Cancer Charity
- Help Adolescents with Cancer
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie Cancer Care
- Muslim Council of Britain
- Muslim Health Network
- National Alliance of Childhood Cancer Parent Organisations
- National Children’s Bureau
- Action for Children (formerly known as) NCH – The Children’s Charity
- Rarer Cancers Foundation
- Skcin - Karen Clifford Skin Cancer Charity
- Skin Care Campaign
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Sue Ryder Care
- Teenage Cancer Trust
- Tenovus
- Well Child
Professional groups
- Association of Cancer Physicians
- British Association for Services to the Elderly
- British Association of Dermatologists
- British Dermatological Nursing Group
- British Geriatrics Society
- British Institute for Radiology
- British Oncological Association (BOA)
- British Psychosocial Oncology Society
- British Skin Foundation
- Cancer Networks Pharmacists Forum
- Cancer Research UK
- National Pharmacy Association
- Primary Care Dermatology Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians, Medical Oncology Joint Special Committee
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society
Others
- Department of Health
- NHS North East Essex
- Solihull NHS Care Trust
- Welsh Assembly Government
|
General
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- NHS Alliance
- NHS Commercial Medicines Unit
- NHS Confederation
- Public Health Wales NHS
- Scottish Medicines Consortium
Comparator manufacturer(s)
- Bayer (dacarbazine)
- Bristol-Myers Squibb (carboplatin)
- Hospira UK (carboplatin
- Medac UK (dacarbazine)
- PLIVA Pharma (carboplatin,dacarbazine)
- Wockhardt UK (carboplatin)
Relevant research groups
- British Society for Dermatological Surgery
- Cochrane Skin Group, Centre of Evidence-based Dermatology, University of Nottingham
- Institute of Cancer Research
- MRC Clinical Trials Unit
- Melanoma Study Group
- Myfanwy Townsend Melanoma Research Fund
- National Cancer Research Institute
- National Cancer Research Network
- Research Institute of the Care of Older People
- Skin Cancer Research Fund
- Skin Research Centre
- Skin Treatment & Research Trust
Evidence Review Group
- Liverpool Reviews & Implementation Group, University of Liverpool
- National Institute for Health Research Health Technology Assessment Programme
Associated guideline groups
- National Collaborating Centre for Cancer
Associated public health groups
|
|
Project history
|
Date
|
Update
|
|
19 April 2012
|
The manufacturer of ipilimumab (Bristol-Myers Squibb) has requested to make a further submission including new clinical data that may address uncertainties in the evidence base considered by the Appraisal Committee. In recognition of the exceptional nature of this request NICE has agreed that the appraisal can be referred back to the Appraisal Committee. The timelines are to be confirmed.
|
|
18 January 2012
|
The manufacturer of ipilimumab (Bristol-Myers Squibb) has requested to make a submission including a patient access scheme. This scheme has been approved by the Department of Health and in recognition of the exceptional circumstances, NICE has agreed that the appraisal can be referred back to the Appraisal Committee.
The appeal stage of this appraisal topic has been suspended. This will allow the manufacturer to submit and the Appraisal Committee to consider new evidence on the cost effectiveness of ipilimumab with the patient access scheme in place.
|
|
23 December 2010
|
Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations.
Therefore, we now anticipate that the appraisal will begin during mid April 2011 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late June 2011.
|
|
18 February 2010
|
Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early January 2011. The deadline for submissions is expected in approximately mid March 2011.
|
|
Key documents
This page was last updated: 18 April 2012
